PTC Therapeutics, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014; year-over-year comparisons are against Q1 2013. Financial amounts below are in millions of dollars unless stated otherwise. PTC is a clinical-stage biopharmaceutical company developing ataluren and other drug candidates. It had no product sales revenue.
Financial performance and position
| Metric | Q1 2014 / March 31, 2014 | Q1 2013 / December 31, 2013 |
|---|---|---|
| Total revenue | $9.2 | $7.1 |
| Research and development expense | $15.9 | $11.3 |
| General and administrative expense | $7.5 | $4.5 |
| Operating loss | $(14.2) | $(8.6) |
| Net loss | $(14.1) | $(14.7) |
| Cash and cash equivalents | $115.9 | $15.4 |
| Marketable securities | $130.7 | $127.1 |
| Total assets | $255.8 | $151.9 |
| Total liabilities | $11.5 | $15.4 |
| Stockholders’ equity | $244.3 | $136.5 |
- Revenue increased 29% year over year. Collaboration revenue rose to $9.1 million, primarily reflecting a $7.5 million Roche milestone after initiation of a Phase 1 spinal muscular atrophy program. Grant revenue declined to $0.1 million from $1.1 million.
- R&D expense increased 41%, mainly from clinical-trial costs and higher share-based compensation. G&A expense increased 69%, reflecting share-based compensation, pre-commercial activity and public-company costs.
- Operating cash use was $13.4 million, versus $7.8 million in Q1 2013. Investing activities used $4.3 million, largely from net purchases of investments. Financing provided $118.1 million, principally from the February follow-on offering; cash increased by $100.4 million during the quarter.
- Cash, cash equivalents and marketable securities totaled $246.6 million. Management estimated these resources, together with expected collaboration research funding, would fund planned operations through 2016, subject to assumptions and risks described below.
- Debt was minimal: the balance sheet reported $12,000 of current long-term debt. Operating and equipment lease obligations totaled $4.3 million, including $0.9 million due within one year.
- No product gross margin is reported because PTC had no product sales. Net loss per share was $0.58 in Q1 2014; the reported Q1 2013 figure of $6,527.30 reflects the recapitalization and a very small weighted-average share count, so it is not directly comparable.
Material changes versus Q1 2013
- Revenue rose $2.1 million, led by the Roche milestone, partly offset by lower grant revenue and lower recognition of deferred collaboration revenue.
- Operating expenses increased by $7.7 million combined. Despite the larger operating loss, net loss narrowed modestly because Q1 2013 included $6.0 million of non-cash interest expense related to convertible-debt discounting; Q1 2014 had net interest income.
- Cash and cash equivalents rose substantially following the February 2014 follow-on offering, which generated $118.2 million in net proceeds. Common shares outstanding were 29.3 million at quarter-end, up from 23.8 million at December 31, 2013.
Outlook, risks and unusual items
- PTC planned to continue the confirmatory Phase 3 trial of ataluren for nonsense-mutation Duchenne muscular dystrophy (nmDMD), begin dosing in a planned Phase 3 trial for nonsense-mutation cystic fibrosis (nmCF) in the first half of 2014, and pursue early-access programs and another ataluren proof-of-concept indication.
- In January 2014, the EMA’s CHMP issued a negative opinion recommending refusal of conditional marketing authorization for ataluren in nmDMD. PTC requested re-examination and expected a final outcome in Q2 2014. The company planned to complete the confirmatory Phase 3 trial before seeking U.S. approval.
- Management expected expenses to increase substantially as clinical development, early-access activity, regulatory work and potential commercialization preparations advanced. The runway estimate through 2016 assumed, among other things, no early EU conditional approval that would trigger significant commercialization spending before completion of the relevant Phase 3 trial. PTC said it could require substantial additional funding; financing may dilute shareholders or require concessions, and may not be available on acceptable terms.
- Development and regulatory outcomes remain uncertain. Earlier ataluren trials did not meet their primary efficacy endpoints at the prespecified statistical significance level; favorable interpretations included retrospective and subgroup analyses. The filing notes regulators may give those analyses less weight. PTC also disclosed disagreements with the FDA on aspects of the proposed nmCF trial design.
- Reported safety considerations included renal-system adverse events and creatinine elevations in an earlier nmCF trial, associated in some cases with concomitant antibiotics; concomitant use was subsequently prohibited in that trial. The filing also discusses modest liver-enzyme elevations in a Phase 1 study.
- EMA site inspections of earlier nmDMD trial sites produced critical and major findings concerning patient eligibility waivers, site oversight and documentation. PTC reported enhanced procedures and proposed corrective actions; further regulatory consequences could require additional studies or affect use of trial data.
- PTC disclosed interest-rate exposure on its short-term investment portfolio. Ordinary-course patient-access claims and disputes were pending; management did not expect their ultimate outcome to materially adversely affect the business.
- Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of March 31, 2014.
Most important facts for investors to verify
- Outcome of the EMA re-examination and any subsequent regulatory requirements for ataluren in nmDMD.
- Enrollment, trial design, timing and results for the confirmatory nmDMD and planned nmCF Phase 3 trials, including FDA alignment on endpoints and duration.
- Whether the reported $246.6 million of cash and marketable securities supports the stated runway through 2016 as development costs rise and under actual regulatory and commercialization timing.
- Progress on corrective actions following EMA clinical-site inspection findings, and whether regulators require further studies or limit reliance on earlier trial data.
- Changes in cash burn, share-based compensation, dilution, collaboration milestones and any financing needs; PTC had no product revenue and remained loss-making.